FDA approves new therapy option for lung cancer patients who develop resistance to early generation EGFR inhibitors

… currently available for lung cancer patients whose tumors contain activating EGFR mutations … more than breast, colon and prostate cancers combined. However, precision medicines, like … to significantly decrease tumor size, 57 percent of lung cancer patients in …